ule-4 Antibody
Description
Expression and Functional Roles
ULBP-4 is expressed in:
-
Immune cells: Activated NK cells, γδ T cells, and CD8+ T cells .
-
Tissues: Epithelial cells, hematopoietic malignancies, and stressed/infected cells .
Key functions:
-
NKG2D-mediated cytotoxicity: Binds NKG2D to activate NK and T-cell responses against infected or transformed cells .
-
γδ T-cell activation: Directly engages TCR γδ and NKG2D to induce cytokine production .
-
Minor histocompatibility antigen: Contributes to graft-versus-host disease (GVHD) in transplant settings .
Table 1: Key Studies on ULBP-4
Antibody Development and Applications
ULBP-4-targeting antibodies are primarily used to study immune activation pathways and therapeutic modulation:
-
Diagnostic tools: Detect ULBP-4 expression in cancer biopsies (e.g., APC-conjugated antibodies for flow cytometry) .
-
Therapeutic potential:
Challenges and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Basic Research Questions
How do I design a humanization strategy for ule-4 antibody while preserving antigen-binding affinity?
Humanization involves grafting complementarity-determining regions (CDRs) from a non-human antibody (e.g., murine) onto a human framework. Key steps:
-
CDR identification: Use Kabat or IMGT numbering to define CDRs .
-
Framework selection: Prioritize human germline frameworks with high homology to the original species (e.g., 85%+ identity) .
-
Critical residue retention: Preserve non-human framework residues critical for CDR orientation (e.g., VH:VL interface residues) .
-
Binding validation: Compare affinity of humanized vs. parental antibody using surface plasmon resonance (SPR) .
Example workflow:
| Step | Method | Outcome Metric |
|---|---|---|
| CDR grafting | Structural alignment tools (PyMOL) | RMSD < 2.0 Å |
| Framework optimization | RosettaAntibody | ΔG < -10 kcal/mol |
| Affinity testing | SPR/BLI | KD ≤ 1 nM |
What experimental controls are essential for validating ule-4 antibody specificity?
-
Negative controls: Use isotype-matched irrelevant antibodies or knockout cell lines .
-
Competition assays: Pre-incubate ule-4 with excess antigen to block binding .
-
Cross-reactivity screening: Test against homologs (e.g., ErbB family receptors for HER2-targeting antibodies) .
Advanced Research Challenges
Approach:
-
Epitope binning: Determine if steric hindrance occurs in physiological conditions .
-
Post-translational modifications: Assess glycosylation impact using LC-MS (e.g., N-linked glycosylation at Asn297) .
-
Tumor penetration studies: Use intravital imaging in xenograft models to evaluate tissue distribution .
What computational tools optimize manufacturability of humanized ule-4 antibodies?
-
Aggregation prediction: Tools like Tango or Aggrescan identify hydrophobic patches .
-
Thermostability enhancement: Molecular dynamics simulations (GROMACS) guided mutagenesis (e.g., IleH69Leu in huMAb4D5) .
-
Case study: A glioblastoma-targeting antibody showed 4x improved expression after framework optimization (VH3-23/VL1-47 germlines) .
How to address immunogenicity risks in ule-4 clinical candidates?
-
Deimmunization pipelines:
Data Analysis & Integration
How to reconcile conflicting results between SPR and ELISA for ule-4-antigen interactions?
| Factor | SPR Artifact | ELISA Artifact | Resolution |
|---|---|---|---|
| Avidity | Monovalent binding | Multivalent binding | Use Fab fragments in SPR |
| Conformation | Native antigen | Denatured antigen | Validate antigen folding (CD spectroscopy) |
| Buffer | Low ionic strength | High nonspecific binding | Standardize buffer (PBS + 0.01% Tween-20) |
What multi-omics strategies link ule-4 mechanism to disease pathways?
-
Transcriptomics: Single-cell RNA-seq of treated vs. untreated tumor microenvironments.
-
Proteomics: Phosphoproteomics to map downstream signaling (e.g., HER2 → PI3K/AKT) .
-
Validation: CRISPRi knockdown of identified pathways to confirm causality .
Methodological Pitfalls
Why does CDR grafting alone fail to restore ule-4 binding affinity?
-
Framework distortions: Non-human residues at H35/H48 disrupt CDR conformation .
-
Solution: Introduce "back-mutations" (e.g., ValH71 → Arg in huMAb4D5) .
